Citadel Advisors’s 89bio ETNB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-126,500
| Closed | -$1.86M | – | 13018 |
|
|
2025
Q3 | $1.86M | Buy |
126,500
+50,800
| +67% | +$518K | ﹤0.01% | 6223 |
|
|
2025
Q2 | $743K | Buy |
75,700
+25,300
| +50% | +$209K | ﹤0.01% | 7722 |
|
|
2025
Q1 | $366K | Sell |
50,400
-31,200
| -38% | -$273K | ﹤0.01% | 9143 |
|
|
2024
Q4 | $638K | Buy |
81,600
+4,700
| +6% | +$38.7K | ﹤0.01% | 8006 |
|
|
2024
Q3 | $569K | Sell |
76,900
-22,800
| -23% | -$192K | ﹤0.01% | 7983 |
|
|
2024
Q2 | $799K | Buy |
99,700
+37,800
| +61% | +$338K | ﹤0.01% | 7045 |
|
|
2024
Q1 | $721K | Buy |
61,900
+3,200
| +5% | +$35.4K | ﹤0.01% | 7608 |
|
|
2023
Q4 | $656K | Sell |
58,700
-4,900
| -8% | -$45K | ﹤0.01% | 7533 |
|
|
2023
Q3 | $982K | Sell |
63,600
-2,600
| -4% | -$43.6K | ﹤0.01% | 6579 |
|
|
2023
Q2 | $1.25M | Sell |
66,200
-127,000
| -66% | -$2.23M | ﹤0.01% | 5991 |
|
|
2023
Q1 | $2.94M | Buy |
193,200
+184,500
| +2,121% | +$2.41M | ﹤0.01% | 4663 |
|
|
2022
Q4 | $111K | Sell |
8,700
-18,100
| -68% | -$163K | ﹤0.01% | 11074 |
|
|
2022
Q3 | $155K | Buy |
+26,800
| New | +$118K | ﹤0.01% | 10665 |
|
|
2022
Q2 | – | Sell |
-11,400
| Closed | -$43K | – | 13162 |
|
|
2022
Q1 | $43K | Buy |
+11,400
| New | +$73.4K | ﹤0.01% | 12894 |
|
Other funds holding ETNB
Citadel Advisors's ETNB Position: Q4 2025 in Review
Citadel Advisors sold out of 89bio (ETNB) in Q4 2025, closing a stake of 151,350 shares — an estimated $2.22M sold.
Citadel Advisors first reported a position in ETNB in Q3 2020 and held it in 21 quarters. The position peaked at $37.7M in Q2 2025. 2 funds tracked by Wall St. Rank hold ETNB as of Q4 2025.
- Citadel Advisors reported no remaining 89bio position as of Q4 2025 after selling out during the quarter.
- Citadel Advisors sold 151,350 89bio shares in Q4 2025, an estimated $2.22M.
- Citadel Advisors first reported a position in 89bio in Q3 2020 and held it in 21 quarters.
- Citadel Advisors's 89bio position peaked at $37.7M in Q2 2025.
- 2 funds tracked by Wall St. Rank held 89bio as of Q4 2025.
Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.